Spotlight Growth
No Result
View All Result
Tuesday, August 16, 2022
  • Login
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

Krystal Biotech, Inc. (NASDAQ: KRYS) Reports Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK to Treat Dystrophic Epidermolysis Bullosa

by admin
November 29, 2021
in Bio/Med/Pharma
0
Krystal Biotech NASDAQ KRYS GEM3 VYJUVEK Spotlight Growth

Krystal Biotech NASDAQ KRYS GEM3 VYJUVEK Spotlight Growth

Krystal Biotech, Inc. (NASDAQ: KRYS) is engaged as a gene therapeutics company, which is focused on the research, development and testing of novel therapies using its redosable gene therapy platform and in-house manufacturing capabilities. Shares of the gene therapeutics company are skyrocketing 118% through early trading on Monday, November 29, 2021. Over the past three months, Krystal Biotech has seen average daily volume of 155,010 shares. However, volume of 4.73 million shares or dollar volume of $412.98 million, has already exchanged hands through early trading Monday.

Shares of Krystal Biotech are surging Monday, after the company announced positive topline results from its pivotal GEM-3 trial of its VYJUVEK candidate for the treatment of dystrophic Epidermolysis Bullosa (dystrophic EB). VYJUVEK is the first non-invasive, topical and redosable gene therapy and the only treatment to take a “genetically corrective” approach to treatment.

The primary endpoint of the trial was to evaluate wound healing using topical VYJUVEK compared to a placebo. Over a six-month period, VYJUVEK’s performance compared to the placebo group showed statistical significance.

Overall, 31 patients were enrolled into the clinical trial. Around 67% of enrolled patients treated with VYJUVEK achieved the primary endpoint of complete wound healing at the six-month mark. This compares to only 22% in the placebo group.

On a secondary endpoint basis, 71% of patients treated with the candidate saw complete wound healing at the three-month point. This compares to only 20% in the placebo group. VYJUVEK was well-tolerated and did not cause any serious drug-related side effects. One mild adverse event was report during the clinical trial.

Dystrophic Epidermolysis Bullosa is referred to as ‘the worst disease you’ve never heard of’ because of the incredibly devastating reality that patients with this genetic condition face, and we are thrilled to announce positive results from our pivotal GEM-3 trial of VYJUVEKTM which showed that this topical gene therapy led to durable wound healing in dystrophic EB wounds,” said Suma Krishnan, Founder and Chief Operating Officer of Krystal. “With these results in hand, we look forward to advancing discussions with regulatory authorities and will work quickly to bring this potential first-ever treatment to patients with dystrophic EB and their families who are in desperate need.”

Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article, but may choose to initiate a position at any time. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.

Tags: biopharmaceuticalsbiotechbiotech stocksbiotechnologyclinical trialscommon stockemerging growthgene therapyinvestinginvesting newsinvestmentKRYSKRYS stockKrystal Biotechmanufacturingmedicalmicrocap stocksNASDAQnasdaq biotechnewspharmaceuticalspublic companyRobinhoodrobinhood armyrobinhood stockssalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stocksstock marketstock market newsstocksstocks to watchtrade ideastraderstradingtreatment
Plugin Install : Widget Tab Post needs JNews - View Counter to be installed
  • Trending
  • Comments
  • Latest
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

Decentraland (MANA) is the Proof of Concept for the Emerging Metaverse

November 22, 2021
Alfi NASDAQ ALF Ridesharing Tablet Rollout Spotlight Growth

Alfi, Inc. (NASDAQ: ALF) Climbs 51% After Entering Into Agreement with Miami-Based Fulfillment & Distribution Center For its Ridesharing Digital Tablet Rollout

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
OLB Group NASDAQ OLB Q2 2022 Earnings Results Spotlight Growth

OLB Group (NASDAQ: OLB) Continues Record Revenue Growth for 2022

August 15, 2022
Viridian Therapeutics NASDAQ VRDN TED Phase 1 2 Clinical Trial Data Spotlight Growth

Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease

August 15, 2022
Twin Vee PowerCats NASDAQ VEEE Q2 2022 Financial Results Spotlight Growth

Twin Vee PowerCats (NASDAQ: VEEE) Releases Q2 2022 Results Showing 158% Increase in Revenue, Completes Spin-Off of Forza X1 (NASDAQ: FRZA)

August 12, 2022
Is Uber Technologies NYSE UBER Finally Investible Spotlight Growth

Is Uber (NYSE: UBER) Finally Investable?

August 11, 2022

Recent News

OLB Group NASDAQ OLB Q2 2022 Earnings Results Spotlight Growth

OLB Group (NASDAQ: OLB) Continues Record Revenue Growth for 2022

August 15, 2022
Viridian Therapeutics NASDAQ VRDN TED Phase 1 2 Clinical Trial Data Spotlight Growth

Viridian Therapeutics (NASDAQ: VRDN) Shares Positive Clinical Data from Phase 1/2 Trial of VRDN-001 for Treatment of Thyroid Eye Disease

August 15, 2022

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us
Spotlight Growth

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2021 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested